[go: up one dir, main page]

WO2011081612A1 - Utilisation de krypton ou de xénon comme agent antiviral - Google Patents

Utilisation de krypton ou de xénon comme agent antiviral Download PDF

Info

Publication number
WO2011081612A1
WO2011081612A1 PCT/UA2010/000012 UA2010000012W WO2011081612A1 WO 2011081612 A1 WO2011081612 A1 WO 2011081612A1 UA 2010000012 W UA2010000012 W UA 2010000012W WO 2011081612 A1 WO2011081612 A1 WO 2011081612A1
Authority
WO
WIPO (PCT)
Prior art keywords
krypton
xenon
animals
agent
antiviral agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/UA2010/000012
Other languages
English (en)
Russian (ru)
Inventor
Виталий Леонидович БОНДАРЕНКО
Александр Петрович ГРАФОВ
Виктор Петрович ЛОЗИЦКИЙ
Олег Юрьевич КАТАШИНСКИЙ
Александр Борисович ЧУДНОВСКИЙ
Владимир Александрович САЧУРА
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from UAU200914027U external-priority patent/UA53797U/ru
Application filed by Individual filed Critical Individual
Publication of WO2011081612A1 publication Critical patent/WO2011081612A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23B—PRESERVATION OF FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES; CHEMICAL RIPENING OF FRUIT OR VEGETABLES
    • A23B2/00—Preservation of foods or foodstuffs, in general
    • A23B2/70—Preservation of foods or foodstuffs, in general by treatment with chemicals
    • A23B2/704—Preservation of foods or foodstuffs, in general by treatment with chemicals in the form of gases, e.g. fumigation; Compositions or apparatus therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Definitions

  • the present invention relates to the field of means for combating viruses, and can be used in medicine, pharmacology, food industry and in other areas where it becomes necessary to destroy viruses.
  • Xenon is the first inert gas for which a chemical compound has been obtained. They are used mainly in powerful gas-discharge light sources, as well as for research and for medical purposes. (“New Polytechnical Dictionary”, Chap. Ed. A.Yu. Ishlinsky Moscow, Scientific Publishing House “Big Russian Encyclopedia”, 2000, p. 253)
  • Iodine belongs to the group of halogen antiseptics (disinfectants) and has a wide spectrum of antimicrobial action. It is active against various types of gram-positive and gram-negative bacteria, fungi, viruses and protozoa.
  • iodine as an antiviral agent is limited, it is used for disinfection or antiseptics, as it leads to irreversible chemical changes in the treated surface, which is especially important when applied to humans or animals.
  • Aldehydes (glutaraldehyde and formaldehyde) are used as an antiviral agent. Active against bacteria, viruses and fungi, but slowly works against tuberculosis bacteria and irritates the skin and eyes
  • aldehydes as an antiviral agent is limited, due to their chemical characteristics, which lead to irreversible chemical changes in the treated surface.
  • Alcohols are used as antiviral agents and have good activity against bacteria and viruses. Ethyl alcohol is most often used in 70% concentration. The use of alcohols as an antiviral agent is also limited by external surfaces, and antiviral activity decreases when the alcohol comes in contact with water - it reduces its concentration. 00012
  • compositions which includes an extract of plant material - plants of the Dioscoreaceae or Plantagmaceae family (patent of the Russian Federation J k 2195308, MKI: A61k35 / 78, publ. 2002.21.27).
  • the known antiviral agent has limited use - as a medicine and cannot be used as a disinfectant or antiseptic substance.
  • the problem to which the invention is directed is to find a new antiviral agent that can be used as a disinfectant, antiseptic or medicinal product, and did not lead to chemical or physical changes in the processing object.
  • the problem is solved by the use of krypton as an antiviral agent.
  • the problem is solved by the use of xenon as an antiviral agent.
  • krypton as an antiviral agent provides a wide range of its use as such: a disinfectant, antiseptic and as a medicine, while the use of krypton does not lead to irreversible changes (physical or chemical) of the processed object, which is due to its chemical inertness, and allows it to be used both for processing objects and for humans and animals, both enterally and parenterally.
  • xenon as an antiviral agent provides a wide range of its use as such: a disinfectant, antiseptic and as a medicine, while the use of krypton does not lead to irreversible changes (physical or chemical) of the treated object, due to its chemical inertness, and allows apply it both to the processing of objects, including food products, and to humans and animals, both enteral and parenteral.
  • Influenza infection in mice weighing 15-18 g was modeled by infecting 100 T1D 50 of influenza A virus / Hong Kong / 1/68 intranasally under mild ether anesthesia. Control animals were not subjected to any manipulation.
  • the research animals were placed in an airtight chamber with a volume of 17 l, in which the air was replaced with a mixture of xenon with oxygen (in the ratio 1: 1) in a volume of 15 l. After every 10 minutes, an additional pumping of the mixture was carried out in the amount of Zl (twice during one room in the chamber). The animals breathed for 30 minutes, then after 30 minutes, during which the animals were outside the chamber and breathed in the usual way, the procedure was repeated. During the day, the animals breathed the mixture 6 times.
  • the treatment was carried out for 5 days. After 1, 3, 5, 7, 10, and 14 days, animals from the control and research groups were individually weighed before slaughter. Totally they took blood, made a blood smear and pulled the lungs, which were weighed. The ratio of lung weight to body weight (in%) was calculated. In the lungs, the amount of the infectious virus was determined by titration on tissue culture of the chorion-allantois membranes of 10-12 day old chicken embryos (CAO).
  • EXAMPLE 2 The antiviral effect of krypton is demonstrated by inhalation in a model of experimental influenza infection in mice.
  • mice of the experimental group after inhalation with krypton for 1 hour were in parallel with control animals infected with 100 ⁇ R50 of influenza virus A / Hong Kong / 1/68 ( ⁇ 3 ⁇ 2) and the mice of the experimental group continued inhalation with krypton for another 1 hour. The next day, the duration of continuous krypton inhalation was 4 hours. After that (1 pore), 5 mice from the control and experimental groups were tested using euthanasia, the lungs were sterilely drawn, in the homogenates of which the amount of the infectious virus was determined by titration on a CAO culture to determine whether krypton had anti-influenza effect upon inhalation use .
  • mice were inhaled with krypton for 1 hour. What remained in peppy mice (5 animals from each group) tested euthanasia 3 and 5 days after the start of the experiment. In the homogenates of the lungs of mice in both groups, the amount of the infectious virus was determined by titration on a HAO culture.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention se rapporte au domaine des moyens de lutte contre les virus, et peut être utilisée en médecine, en pharmacologie, dans l'industrie alimentaire ainsi que dans d'autres domaines où il est nécessaire de détruire des virus. L'utilisation de krypton ou de xénon en qualité d'agent antiviral offre une grande plage d'applications de celui-ci en qualité d'agent désinfectant, d'antiseptique, et d'agent thérapeutique. Son utilisation n'entraîne aucun changement irréversible (physique ou chimique) de l'objet traité du fait de son inertie chimique, et permet de l'utiliser pour le traitement d'objets, comme des produits alimentaires, ou d'êtres humains et d'animaux que ce soit par voie entérale ou parentérale. Etant donné que le krypton et le xénon sont des gaz, ils peuvent être utilisés non seulement sous des formes traditionnelles pour de tels besoins, c'est-à-dire des formes liquides (comme pour un agent antiseptique ou désinfectant ou un agent thérapeutique) ou solides (agent thérapeutique), mais aussi sous forme d'aérosols, ce qui assure le traitement simultané de cavités externes et internes dans un même temps, et ce qui est particulièrement important pour les êtres humains et les animaux.
PCT/UA2010/000012 2009-12-31 2010-04-06 Utilisation de krypton ou de xénon comme agent antiviral Ceased WO2011081612A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
UAU200914027U UA53797U (ru) 2009-12-31 2009-12-31 Употребление инертного газа криптона и/или ксенона в качестве действующих веществ в составе лекарственной формы
UAU200914027 2009-12-31
UAA201002270 2010-03-01
UA201002270 2010-03-01

Publications (1)

Publication Number Publication Date
WO2011081612A1 true WO2011081612A1 (fr) 2011-07-07

Family

ID=44226722

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/UA2010/000012 Ceased WO2011081612A1 (fr) 2009-12-31 2010-04-06 Utilisation de krypton ou de xénon comme agent antiviral

Country Status (1)

Country Link
WO (1) WO2011081612A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000067806A1 (fr) * 1999-05-05 2000-11-16 Milcitec Management S.A. Agents de desinfection et de sterilisation a base de composes de xenon
RU2001126525A (ru) * 1999-03-11 2003-06-27 Ага Аб Применение ксенона для лечения нейроинтоксикаций
RU2232013C2 (ru) * 2001-06-04 2004-07-10 Закрытое акционерное общество "Специальное конструкторское бюро экспериментального оборудования при Государственном научном центре Российской Федерации "Институт медико-биологических проблем" РАН" Способ воздействия газовых смесей на организм
US6805701B1 (en) * 1998-07-28 2004-10-19 Marta Cortes Method of enhancing immune response
RU2346695C2 (ru) * 2006-08-15 2009-02-20 Общество с ограниченной ответственностью "Ксиан"(ООО "Ксиан") Применение ксенона для коррекции патологических изменений в организме, связанных с нарушением антиоксидантного статуса
US7503322B2 (en) * 2003-09-12 2009-03-17 Harris Michael F Methods for the treatment of HIV and other viruses

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19910986C2 (de) * 1999-03-11 2001-06-07 Aga Ab Verwendung von Xenon bei der Behandlung von Neurointoxikationen

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6805701B1 (en) * 1998-07-28 2004-10-19 Marta Cortes Method of enhancing immune response
RU2001126525A (ru) * 1999-03-11 2003-06-27 Ага Аб Применение ксенона для лечения нейроинтоксикаций
WO2000067806A1 (fr) * 1999-05-05 2000-11-16 Milcitec Management S.A. Agents de desinfection et de sterilisation a base de composes de xenon
RU2232013C2 (ru) * 2001-06-04 2004-07-10 Закрытое акционерное общество "Специальное конструкторское бюро экспериментального оборудования при Государственном научном центре Российской Федерации "Институт медико-биологических проблем" РАН" Способ воздействия газовых смесей на организм
US7503322B2 (en) * 2003-09-12 2009-03-17 Harris Michael F Methods for the treatment of HIV and other viruses
RU2346695C2 (ru) * 2006-08-15 2009-02-20 Общество с ограниченной ответственностью "Ксиан"(ООО "Ксиан") Применение ксенона для коррекции патологических изменений в организме, связанных с нарушением антиоксидантного статуса

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KHARKEVICH D.A.: "Meditsina", FARMAKOLOGIA, MOSCOW, 1996, pages 452 - 453 *

Similar Documents

Publication Publication Date Title
CA2761710C (fr) Methodes de traitement ou de prevention d'une maladie associee a la grippe avec des solutions aqueuses a potentiel d'oxydoreduction
Banovic et al. Diluted sodium hypochlorite (bleach) in dogs: antiseptic efficacy, local tolerability and in vitro effect on skin barrier function and inflammation
KR20060037390A (ko) 이소프로필 알코올, 참깨오일, 알로에, 레몬 오일이 함유된무독성 점막의 살균제
Amin Biological assessment of ozone therapy on experimental oral candidiasis in immunosuppressed rats
CN102265893B (zh) 一种抗微生物的组合物及其应用
Geitani et al. Bactericidal effects and stability of LL-37 and CAMA in the presence of human lung epithelial cells
WO2011081612A1 (fr) Utilisation de krypton ou de xénon comme agent antiviral
RS51938B (sr) Proizvodnja vijabilne suspenzije sa jajima crva koja može da se skladišti
Wolska et al. The potential of metal nanoparticles for inhibition of bacterial biofilms
Callisperis et al. Chlorine dioxide and chlorite as treatments for diabetic foot ulcers
CN111328811B (zh) 一种低浓度酒精杀菌消毒液及其应用
KR20240016954A (ko) 분별된 꿀을 사용한 병태 치료용 조성물 및 방법
KR20230145023A (ko) 미생물 감염을 소독, 치료 및 예방하기 위한 조성물 및 방법
RU2825642C1 (ru) Интраназальная композиция для профилактики и/или лечения инфекций вирусной и бактериальной этиологии
KR20060054190A (ko) 코로나 바이러스를 불활성화시키는 제제
Allan et al. Innate immune cocktail partially protects broilers against cellulitis and septicemia
KR102277638B1 (ko) 병원성 미생물 소독용 조성물과 도서소독장치
RU2753609C1 (ru) Противовирусное гуминовое средство
RU2392003C2 (ru) Способ получения сальмонеллезной вакцины
JP2005068089A (ja) コロナウイルス消毒剤
TR2022020608A2 (tr) Anti̇vi̇ral burun spreyi̇
KR20240118125A (ko) 분획된 꿀을 사용하는 생물막의 파괴 방법 및 조성물
Khan et al. Treatment and control strategies for COVID-19: Prospects and possibilities.
WO2023009080A1 (fr) Médicament antiviral, antibactérien à base de plantes pour prévention de transmission et de propagation des maladies transmises par voie respiratoire et contact de surface
RU2354405C2 (ru) Дезинфицирующее средство

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10841383

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10841383

Country of ref document: EP

Kind code of ref document: A1